Focused Ultrasound and Gemcitabine in Breast Cancer
NCT: NCT04796220 · ACTIVE_NOT_RECRUITING
Brief Summary
This study will test the use of focused ultrasound ablation, low-dose gemcitabine (a chemotherapy) and the combination of focused ultrasound ablation plus low-dose gemcitabine in patients with early-stage breast cancers. We will be testing the effects of each of these regimens on cells in the immune system. We hypothesize that the combination of focused ultrasound ablation and gemcitabine will decrease myeloid-derived suppressor cells and will increase T cell activity. We also hypothesize that focused ultrasound ablation and low-dose gemcitabine will be safe and will result in non-inferior surgical completion rates and tumor margin assessments.
Frequently Asked Questions
What is Focused Ultrasound and Gemcitabine in Breast Cancer?
Focused Ultrasound and Gemcitabine in Breast Cancer is a clinical trial registered under NCT04796220. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT04796220?
The current status of NCT04796220 (Focused Ultrasound and Gemcitabine in Breast Cancer) is: ACTIVE_NOT_RECRUITING.
When did Focused Ultrasound and Gemcitabine in Breast Cancer start?
Focused Ultrasound and Gemcitabine in Breast Cancer started on 2022-01-27.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.